scholarly article | Q13442814 |
P50 | author | Lena Claesson-Welsh | Q4942989 |
Magdalena Chrzanowska-Wodnicka | Q57204445 | ||
Kishore K Wary | Q96152283 | ||
Vijay Avin Balaji Ragunathrao | Q99566205 | ||
P2093 | author name string | Viswanathan Natarajan | |
Asrar B Malik | |||
Dolly Mehta | |||
Arkadiusz Z Dudek | |||
Alejandra Chavez | |||
Mumtaz Anwar | |||
Jan K Kitajewski | |||
Sribalaji Lakshmikanthan | |||
De Yu Mao | |||
Md Zahid Akhter | |||
P2860 | cites work | The inducible G protein-coupled receptor edg-1 signals via the G(i)/mitogen-activated protein kinase pathway | Q24310250 |
The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis | Q24339531 | ||
VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis | Q24530176 | ||
Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
Export of sphingosine-1-phosphate and cancer progression | Q27009557 | ||
Tumor angiogenesis: therapeutic implications | Q27860595 | ||
Epsins: adaptors in endocytosis? | Q27939888 | ||
GEFs and GAPs: critical elements in the control of small G proteins | Q28304540 | ||
TrkB binds and tyrosine-phosphorylates Tiam1, leading to activation of Rac1 and induction of changes in cellular morphology | Q28505203 | ||
Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice | Q28508807 | ||
Molecular mechanisms and clinical applications of angiogenesis | Q29547314 | ||
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis | Q29614537 | ||
VEGF receptor signalling - in control of vascular function | Q29617256 | ||
Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells | Q30579734 | ||
Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth | Q30582575 | ||
Endothelial β-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System Homeostasis | Q30734754 | ||
Tiam-Rac signaling mediates trans-endocytosis of ephrin receptor EphB2 and is important for cell repulsion. | Q30810814 | ||
Morphological observation and in vitro angiogenesis assay of endothelial cells isolated from human cerebral cavernous malformations | Q33275470 | ||
FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. | Q33422807 | ||
ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. | Q33755332 | ||
Mesenchymal-endothelial transition contributes to cardiac neovascularization. | Q34429225 | ||
VEGF receptor signal transduction | Q34461939 | ||
VEGF-targeted therapy: mechanisms of anti-tumour activity. | Q34791610 | ||
S1PR1 Tyr143 phosphorylation downregulates endothelial cell surface S1PR1 expression and responsiveness | Q35126954 | ||
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. | Q35568516 | ||
VEGF-induced vascular permeability is mediated by FAK. | Q35697402 | ||
Point-counterpoint of sphingosine 1-phosphate metabolism | Q35732398 | ||
Tumor microenvironment and progression | Q35752272 | ||
VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors | Q35977376 | ||
The outs and the ins of sphingosine-1-phosphate in immunity | Q36011196 | ||
Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development | Q36236992 | ||
Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor | Q36478465 | ||
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene | Q36525865 | ||
Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. | Q36527182 | ||
Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. | Q36627430 | ||
Targeting VEGF-A to treat cancer and age-related macular degeneration | Q36628552 | ||
VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread | Q36747249 | ||
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases | Q36851400 | ||
Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions | Q36901312 | ||
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. | Q37031917 | ||
Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells | Q37255365 | ||
Conditional deletion of FAK in mice endothelium disrupts lung vascular barrier function due to destabilization of RhoA and Rac1 activities. | Q37475670 | ||
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. | Q37578166 | ||
STIM1 Phosphorylation at Y361 Recruits Orai1 to STIM1 Puncta and Induces Ca2+ Entry. | Q37652236 | ||
Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation sites in vivo | Q37726630 | ||
Dynamics of endothelial cell behavior in sprouting angiogenesis | Q37785355 | ||
Developmental and pathological angiogenesis | Q37901035 | ||
Sphingosine 1-phosphate signalling in cancer | Q37977171 | ||
VEGFA and tumour angiogenesis. | Q38065328 | ||
Angiogenesis versus arteriogenesis: neuropilin 1 modulation of VEGF signaling | Q38450860 | ||
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia | Q38893850 | ||
Mechanisms and regulation of endothelial VEGF receptor signalling. | Q38909541 | ||
Selective Targeting of a Novel Epsin-VEGFR2 Interaction Promotes VEGF-Mediated Angiogenesis. | Q39185970 | ||
S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration | Q39700512 | ||
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression | Q39719008 | ||
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis | Q40713163 | ||
Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy | Q41960388 | ||
Endothelial cells contribute to generation of adult ventricular myocytes during cardiac homeostasis | Q42090077 | ||
VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation. | Q42292864 | ||
Translocation of the Rac1 guanine nucleotide exchange factor Tiam1 induced by platelet-derived growth factor and lysophosphatidic acid | Q42803959 | ||
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types | Q42820704 | ||
The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. | Q43563466 | ||
Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. | Q44465055 | ||
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. | Q44928916 | ||
Sphingosine 1-phosphate-induced mobilization of intracellular Ca2+ mediates rac activation and adherens junction assembly in endothelial cells | Q45280517 | ||
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. | Q45981705 | ||
Role of Sphingosine Kinase 1 and S1P Transporter Spns2 in HGF-mediated Lamellipodia Formation in Lung Endothelium | Q46457450 | ||
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models | Q46853200 | ||
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization | Q46882679 | ||
S1P1 inhibits sprouting angiogenesis during vascular development | Q47073640 | ||
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. | Q47340303 | ||
Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury | Q47678443 | ||
Atomic view of the energy landscape in the allosteric regulation of Abl kinase. | Q47748395 | ||
The Tiam1 guanine nucleotide exchange factor is auto-inhibited by its pleckstrin homology coiled-coil extension domain. | Q47838338 | ||
Kinase inhibitors: the road ahead. | Q52653219 | ||
Tumor-associated endothelial cells with cytogenetic abnormalities. | Q54692960 | ||
Sox17 is required for endothelial regeneration following inflammation-induced vascular injury | Q64060414 | ||
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition | Q91760986 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 11 | |
P304 | page(s) | 3472-3487.e4 | |
P577 | publication date | 2019-12-01 | |
P1433 | published in | Cell Reports | Q5058165 |
P1476 | title | Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling | |
P478 | volume | 29 |
Q90313684 | Advancements in understanding the role of lysophospholipids and their receptors in lung disorders including bronchopulmonary dysplasia |
Q99604380 | Epigenetic response to hyperoxia in the neonatal lung is sexually dimorphic |
Q99566206 | S1PR1 and VEGFR2 - a synergy that promotes tumor angiogenesis? |
Search more.